This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
3D Atopic Dermatitis Model
Alcyomics Atopic Dermatitis Models - Advancing Research for Skin Health Solutions
Are you searching for cutting-edge models to explore atopic dermatitis and develop breakthrough treatments? Look no further! Alcyomics is delighted to introduce our state-of-the-art Atopic Dermatitis Models, designed to accelerate your understanding of this complex skin condition.
Unraveling Atopic Dermatitis Pathways:
Atopic dermatitis is a multifactorial skin disorder with intricate underlying mechanisms. Alcyomics' Atopic Dermatitis Models faithfully replicate the key aspects of the disease, offering a platform to study disease progression, immune responses, and potential therapeutic interventions.
Customized Solutions for Precise Research:
At Alcyomics, we recognize the diversity of research needs. Our Atopic Dermatitis Models are fully customizable, enabling you to tailor the models to fit your specific research objectives. Whether it's studying inflammation, immune cell interactions, or assessing novel therapies, we have you covered.
Our Models:
Skimune® AD
Based on human tissue skin explants, our advanced Skimune® model stimulated to demonstrate an AD phenotype through addition of inflammatory cytokines and autologous immune cells.
Skimune® Epi AD
Based on our Skimune® Epi platform, Skimune® Epi AD exhibits key phenotypical markers of AD in a 96 well plate high throughput format, perfect for larger scale screening requirements.
Unraveling Atopic Dermatitis Pathways:
Atopic dermatitis is a multifactorial skin disorder with intricate underlying mechanisms. Alcyomics' Atopic Dermatitis Models faithfully replicate the key aspects of the disease, offering a platform to study disease progression, immune responses, and potential therapeutic interventions.
Customized Solutions for Precise Research:
At Alcyomics, we recognize the diversity of research needs. Our Atopic Dermatitis Models are fully customizable, enabling you to tailor the models to fit your specific research objectives. Whether it's studying inflammation, immune cell interactions, or assessing novel therapies, we have you covered.
Our Models:
Skimune® AD
Based on human tissue skin explants, our advanced Skimune® model stimulated to demonstrate an AD phenotype through addition of inflammatory cytokines and autologous immune cells.
Skimune® Epi AD
Based on our Skimune® Epi platform, Skimune® Epi AD exhibits key phenotypical markers of AD in a 96 well plate high throughput format, perfect for larger scale screening requirements.
Skimune® AD
Real human tissues represent the complexity of in vivo biology
Induced through validated cytokine cocktails and autologous PBMCs to mimic typical Atopic dermatitis responses
Does not rely on patient derived samples
Reduces variability caused by pre-existing treatment regimes
Validated for mechanistic assessment of steroid formulations and monoclonal antibodies
Get in touchSkimune® AD is a human explant model which is induced to express an Atopic Dermatitis phenotype through co-culture with autologous immune cells and an inflammatory cytokine cocktail.
Markers for AD phenotypes such as Filaggrin and Thymic Stromal Lyphoprotein (TSLP) are lowered and raised respectively in Skimune® AD similarly to that observed in clinical patient samples (Figure 1). These biomarkers can be detected by immunohistochemistry and quantified in supernatants using ELISA to demonstrate significant differences between stimulated tissues and unstimulated controls (Figure 2). Application of standard AD therapeutics such as hydrocortisone was able to reverse the AD induced phenotype (Figure 1). Skimune® AD is a powerful tool for AD research.
Figure 1 - H&E and immunostaining for TSLP in control, AD induced, 1% Hydrocortisone treated, and 0.05% Clobetasol Propionate treated conditions. TSLP staining is dramatically reduced in treated samples.
Figure 2 - ELISA analysis of supernatant Filaggrin and TSLP shows disease specific changes in AD induced models.
The Alcyomics Advantage:
Cutting-Edge Technology: Experience the latest advancements in skin tissue engineering and 3D modeling, ensuring realistic and physiologically relevant representations of atopic dermatitis.
Human-Relevant Models: Our models utilize human-derived cells, providing a more accurate reflection of the disease's complexity and response to treatments.
Comprehensive Evaluation: Assess disease biomarkers, immune cell activation, and drug responses within our models, generating comprehensive data for in-depth analysis.
Collaborative Expertise: Work closely with our team of skin biology experts and scientists, who are dedicated to guiding your research journey to success.
Translational Impact: Leverage our models to bridge the gap between preclinical and clinical studies, facilitating smoother translation of discoveries to clinical applications.
Cutting-Edge Technology: Experience the latest advancements in skin tissue engineering and 3D modeling, ensuring realistic and physiologically relevant representations of atopic dermatitis.
Human-Relevant Models: Our models utilize human-derived cells, providing a more accurate reflection of the disease's complexity and response to treatments.
Comprehensive Evaluation: Assess disease biomarkers, immune cell activation, and drug responses within our models, generating comprehensive data for in-depth analysis.
Collaborative Expertise: Work closely with our team of skin biology experts and scientists, who are dedicated to guiding your research journey to success.
Translational Impact: Leverage our models to bridge the gap between preclinical and clinical studies, facilitating smoother translation of discoveries to clinical applications.
Skimune® Epi AD
Benefits of Skimune® Epi AD are:
Cytokine induced epidermal model allows for high throughput assessment of disease modifying treatments
Get in touchAlcyomics is also in the process of developing an epidermal Atopic Dermatitis model for high throughput screening needs.
Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models.
Alcyomics is also in the process of developing an epidermal Atopic Dermatitis model for high throughput screening needs.
Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models.
Some benefits of using Skimune Epi AD:
Reproducibility: In vitro models allow for greater control over experimental conditions, leading to improved reproducibility of results. Researchers can standardize variables, minimizing experimental variability.
Flexibility and Customizability: In vitro models offer the flexibility to modify experimental parameters, enabling researchers to design custom experiments to suit specific research questions.
High Throughput Screening: In vitro models are amenable to high-throughput screening, allowing researchers to test multiple compounds or treatments simultaneously, accelerating drug discovery and development.
Reduced Interference: In traditional tissue-based models, extracellular factors, and systemic interactions can influence experimental outcomes. In vitro models provide a more controlled environment, reducing interference from external factors.
Accelerated Studies: In vitro models often have shorter experimental timelines compared to studies involving live organisms, enabling researchers to obtain results more quickly.
Safety and Regulatory Compliance: In vitro models can serve as initial screens to assess the safety and potential toxicity of new compounds before advancing to animal or human studies, ensuring regulatory compliance.
Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models.
Alcyomics is also in the process of developing an epidermal Atopic Dermatitis model for high throughput screening needs.
Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models.
Some benefits of using Skimune Epi AD:
Reproducibility: In vitro models allow for greater control over experimental conditions, leading to improved reproducibility of results. Researchers can standardize variables, minimizing experimental variability.
Flexibility and Customizability: In vitro models offer the flexibility to modify experimental parameters, enabling researchers to design custom experiments to suit specific research questions.
High Throughput Screening: In vitro models are amenable to high-throughput screening, allowing researchers to test multiple compounds or treatments simultaneously, accelerating drug discovery and development.
Reduced Interference: In traditional tissue-based models, extracellular factors, and systemic interactions can influence experimental outcomes. In vitro models provide a more controlled environment, reducing interference from external factors.
Accelerated Studies: In vitro models often have shorter experimental timelines compared to studies involving live organisms, enabling researchers to obtain results more quickly.
Safety and Regulatory Compliance: In vitro models can serve as initial screens to assess the safety and potential toxicity of new compounds before advancing to animal or human studies, ensuring regulatory compliance.
Figure 3 - Skimune Epi AD demonstrates changes in structure though histological assesment and disease specific changes in protein expression such as Filaggrin and TSLP
